March 20, 2023 4:51pm

After a week of “idiot management” and more “bad actions” are coming out at Silicon Valley Bank (SVB) that endangered the sector as a whole that will be slow to come back

News: Sangamo Therapeutics (SGMO -$0.08) partnerships have walked - with Novartis (NVS) and Biogen (BIIB) saying good-bye

Pre-open indication Results: 3 Hits and 3 Miss

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!  

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +382.60 points (+1.20%), the S&P closed UP +34.93 points (+0.89%) while the Nasdaq closed UP +45.03 points (+0.39%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes Stocks rose Monday, as investors grew hopeful that a crisis in the banking sector may be easing.

“The instability in the financial sector over the past two weeks raises the stakes for the Federal Reserve’s interest rate decision on Wednesday.” <CNBC>

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences

  • Monday’s advance/decline line opened negative at 11 up/ 22 down and 2 flats, stayed negative with 10 up/ 22 down and 3 flats at the mid-day, ending with a negative close of 13/21 and 1 flat

 

Pre-open indication Results: 3 Hits < Prime Medicine (PRME +$0.61), Beam Therapeutics (BEAM -$0.99), bluebird bio (BLUE -$0.07)> 3 Miss < Vericel (VCEL +$0.63), Compass Therapeutics (CMPX - $0.19), Solid Biosciences (SLDB -$0.43)

52-week low:

·         Caribou Biosciences (CRBU) at $4.88

·         Sangamo Therapeutics (SGMO) at $1.93

·         Solid Biosciences (SLDB) at $3.68

·         Homology Medicine (FIXX) at $0.94

·         Cellectis SA (CLLS) at $1.78

 

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … https://www.regmedinvestors.com/articles/12843 - 26 of 35

RegMed Investors (RMi) Research Note: Upcoming Q4 earnings reporting dates … https://www.regmedinvestors.com/articles/12830

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was up +1.08% and the XBI was up +0.37%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -1.38 points or -5.41% at 24.13

 

Closing Down (10 of 21):

  • Intellia Therapeutics (NTLA -$1.57 after Friday’s -$0.71),
  • CRISPR Therapeutics (CRSP -$1.28 after Friday’s +$0.35)
  • Beam Therapeutics (BEAM -$0.99 after Friday’s -$2.29),
  • BioLife Solutions (BLFS -$0.54 after Friday’s +$1.54),
  • Solid Biosciences (SLDB -$0.43 after Friday’s -$0.51),
  • Compass Therapeutics (CMPX -$0.19),
  • Voyager Therapeutics (VYGR -$0.19),
  • Chinook Therapeutics (KDNY -$0.17),
  • Editas Medicine (EDIT -$0.17),
  • MiMedx (MDXG -$0.17),

Flat (1)

  • Precigen (PGEN)

Closing Up (10 of 13):

  • Alnylam Pharmaceuticals (ALNY +$2.07 after Friday’s -$4.21),
  • Sage Therapeutics (SAGE +$1.23 after Friday’s -$0.89),
  • Regenxbio (RGNX +$0.75 after Friday’s -$0.94),
  • Vericel (VCEL +$0.63 after Friday’s -$1.60),
  • Prime Medicine (PRME +$0.61 after Friday’s -$0.92),
  • Ultragenyx (RARE +$0.47 after Friday’s -$1.69),
  • Ionis Pharmaceuticals (IONS +$0.42 after Friday’s +$0.18),
  • AxoGen (AXGN +$0.26),
  • Mesoblast (MESO +$0.06),
  • Avrobio (AVRO+$0.04 after Friday’s +$0.06)

 

Q1/23 – March

  • Monday closed negative with 13 incliner, 21 decliners and 1 flat
  • Friday closed negative with 7 incliner, 28 decliners and 0 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

As I had stated last week, “The sector’s WHIPLASH is NOT over” and it wasn’t!

“U.S. stocks are wavering as risk aversion won't be going away until markets are confident that the Fed is done with their rate hiking campaign," Oanda senior market analyst Edward Moya said in a note to clients. The banking system still doesn't have any confidence as Wall Street tries to send yields sharply lower, he says.” <IBD>

The rush of Q4 and FY22 earnings to release is on … 26 of my 35 covered have reported.

Upcoming Q4 earnings reporting will present challenges to share pricing.

·         Nine (9) more releases forthcoming of my 35 covered companies

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

 

Remember, there are four (4) phases of the stock cycle: accumulation; markup; distribution; and markdown.

As I have stated, “What goes up with ceremony, goes down with disdain followed by the opposite effect.”

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

The NO spin zone!

 

Biostage (OTCQB: BSTG) – still pumping the volume by promoting the share price!!

Monday closed down -$0.10 with 498 shares traded after Friday closed up +$0.45 with 1,590 shares traded following Thursday’s +$0.09 with 3,924 shares traded after Wednesday closed down -$0.44 with 4,166 shares traded, Tuesday closed down -$0.02 with 5,105 shares traded and the previous Monday’s +$0.26 with 10,1190 shares traded <3-month average volume = 1,650 shares>

·         Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold??

·         Let’s also welcome a NEW accounting firm – the fourth (4th) in five (5) years. When will they resign …??

·         Where is the SEC??

·         NEW Auditors must consider whether there is substantial doubt about a company’s ability to continue as a going concern, an assessment of the company’s viability over the next year.

·         Continuing as an “going cocern”!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.